Researchers are projecting that, by 2050, there will be 35.3 million people with cancer and 18.5 million cancer deaths worldwide.

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response ...

The highly acclaimed Black Health Matters Summit returns to Atlanta with vital health screenings, influential speakers, special guest appearances, and trusted resources, aimed at mobilizing the ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...

Multiple myeloma was once viewed as an incurable diagnosis, but Ameet Patel, MD, of Florida Cancer Specialists & Research ...

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient ...

Colleen Mabasa, a patient with multiple myeloma, sat down with CURE for an interview to discuss how she pursued chimeric antigen receptor (CAR)-T cell therapy, navigated insurance and logistical ...

A pre-trial hearing was held Thursday, where the city of Austin refused to accept Suzanne LaFollette's claim.

You can take actions to help protect yourself from cancer—and your state can too with systematic interventions, such as policies, programs, and educational campaigns, to reduce cancer risk factors and ...